Revvity, Inc. RVTY
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, Revvity, Inc. gets an algorithmic score of 52/100. It trades at 152.77 $, with a bullish technical trend (RSI 74.8) and 39.1% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low-debt balance sheet.
- Meaningful dividend (18.00%).
Weaknesses
- Low ROE (3.2%).
- Shrinking revenue (-4.8% per year).
Fundamentals
| P/E | 73.45 |
| Forward P/E | 25.93 |
| PEG | 0.73 |
| P/B | 2.36 |
| EV/EBITDA | 22.11 |
| P/S | 5.85 |
| ROE % | 3.21 |
| ROA % | 2.37 |
| Gross margin % | 54.98 |
| Operating margin % | 17.05 |
| Net margin % | 8.16 |
| Revenue growth % (y/y) | 1.30 |
| Earnings growth % (y/y) | 1.20 |
| Revenue CAGR % | -4.82 |
| Earnings CAGR % | -24.89 |
| Debt/Equity % | 46.23 |
| Current ratio | 1.80 |
| FCF yield % | 2.99 |
| Dividend yield % | 18.00 |
| Payout % | 13.46 |
Returns
| 1 month | +18.6 % |
| 3 months | +37.4 % |
| 6 months | +80.5 % |
| YTD | +56.0 % |
| 1 year | +82.2 % |
| 3 years | +40.6 % |
| 5 years | -16.3 % |
Risk
| 1-year volatility | 39.1 % |
| Beta | 1.06 |
| 5-year max drawdown | -59.0 % |
| Sharpe 1A | 1.63 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.